(600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 600664 · · 3 pages · Chinese
Summary by 6ix AI
Investors can submit questions in advance through the designated platform before the event. The company aims to provide insights into its operational results and financial status during the meeting.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Harbin Pharmaceutical Group Co., Ltd. on 6ix
Story so far
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on the Subordinate Enterprise's Drug Passing the Generic Drug Consistency Evaluation
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on Amendment to the Articles of Association
Earlier from Harbin Pharmaceutical
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on the Subordinate Enterprise's Drug Passing the Generic Drug Consistency Evaluation
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Report for Q3 2026
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 29th Meeting of the 10th Board of Directors
- (600664)"Harbin Pharmaceutical Group Co., Ltd."Announcement on Amendment to the Articles of Association
Follow Harbin Pharmaceutical into a list and get an email when it puts out news.
Follow Harbin Pharmaceutical